Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Vladimir Tolmachev
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Anatomy
Chemicals & Drugs
Concepts & Ideas
Living Beings
Procedures
Disorders
Sign-in to see full Profile
Network (preview)
45
Orlova, Anna
39
Lundqvist, Hans
28
Carlsson, Jörgen
17
Gedda, Lars
15
Sundin, Anders
11
Lubberink, Mark
11
Nilsson, Fredrik
10
Sandström, Mattias
10
Bruskin, Alexander
9
Persson, Mikael
9
Feldwisch, Joachim
9
Abrahmsén, Lars
9
Widström, Charles
9
Wennborg, Anders
8
Sjöberg, Stefan
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Vladimir Tolmachev (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Tran Thuy A; Rosik Daniel; Abrahmsén Lars; Sandström Mattias; Sjöberg Anna; Wållberg Helena; Ahlgren Sara; Orlova Anna; Tolmachev Vladimir
Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.
European journal of nuclear medicine and molecular imaging 2009;36(11):1864-73.
-
2009: Tolmachev Vladimir; Wållberg Helena; Andersson Karl; Wennborg Anders; Lundqvist Hans; Orlova Anna
The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
European journal of nuclear medicine and molecular imaging 2009;36(9):1460-8.
-
2009: Ekblad Torun; Orlova Anna; Feldwisch Joachim; Wennborg Anders; Karlström Amelie Eriksson; Tolmachev Vladimir
Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.
Bioorganic & medicinal chemistry letters 2009;19(14):3912-4.
-
2009: Ahlgren Sara; Wållberg Helena; Tran Thuy A; Widström Charles; Hjertman Magnus; Abrahmsén Lars; Berndorff Dietmar; Dinkelborg Ludger M; Cyr John E; Feldwisch Joachim; Orlova Anna; Tolmachev Vladimir
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(5):781-9.
-
2009: Tolmachev Vladimir; Mume Eskender; Sjöberg Stefan; Frejd Fredrik Y; Orlova Anna
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.
European journal of nuclear medicine and molecular imaging 2009;36(4):692-701.
-
2009: Orlova Anna; Wållberg Helena; Stone-Elander Sharon; Tolmachev Vladimir
On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(3):417-25.
-
2009: Tolmachev Vladimir; Friedman Mikaela; Sandström Mattias; Eriksson Tove L J; Rosik Daniel; Hodik Monika; Ståhl Stefan; Frejd Fredrik Y; Orlova Anna
Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(2):274-83.
-
2009: Ekblad Torun; Tolmachev Vladimir; Orlova Anna; Lendel Christofer; Abrahmsén Lars; Karlström Amelie Eriksson
Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody.
Biopolymers 2009;92(2):116-23.
-
2008: Tran Thuy A; Ekblad Torun; Orlova Anna; Sandström Mattias; Feldwisch Joachim; Wennborg Anders; Abrahmsén Lars; Tolmachev Vladimir; Eriksson Karlström Amelie
Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
Bioconjugate chemistry 2008;19(12):2568-76.
-
2008: Tolmachev Vladimir; Xu Heng; Wållberg Helena; Ahlgren Sara; Hjertman Magnus; Sjöberg Anna; Sandström Mattias; Abrahmsén Lars; Brechbiel Martin W; Orlova Anna
Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
Bioconjugate chemistry 2008;19(8):1579-87.
-
2008: Steffen Ann-Charlott; Göstring Lovisa; Tolmachev Vladimir; Palm Stig; Stenerlöw Bo; Carlsson Jörgen
Differences in radiosensitivity between three HER2 overexpressing cell lines.
European journal of nuclear medicine and molecular imaging 2008;35(6):1179-91.
-
2008: Nordberg E; Orlova A; Friedman M; Tolmachev V; Ståhl S; Nilsson F Y; Glimelius B; Carlsson J
In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.
Oncology reports 2008;19(4):853-7.
-
2008: Friedman Mikaela; Orlova Anna; Johansson Eva; Eriksson Tove L J; Höidén-Guthenberg Ingmarie; Tolmachev Vladimir; Nilsson Fredrik Y; Ståhl Stefan
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
Journal of molecular biology 2008;376(5):1388-402.
-
2008: Ahlgren Sara; Orlova Anna; Rosik Daniel; Sandström Mattias; Sjöberg Anna; Baastrup Barbro; Widmark Olof; Fant Gunilla; Feldwisch Joachim; Tolmachev Vladimir
Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
Bioconjugate chemistry 2008;19(1):235-43.
-
2008: Tolmachev V
Imaging of HER-2 overexpression in tumors for guiding therapy.
Current pharmaceutical design 2008;14(28):2999-3019.
-
2007: Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V
Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2007;51(4):314-23.
-
2007: Tran Thuy; Engfeldt Torun; Orlova Anna; Sandström Mattias; Feldwisch Joachim; Abrahmsén Lars; Wennborg Anders; Tolmachev Vladimir; Karlström Amelie Eriksson
(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Bioconjugate chemistry 2007;18(6):1956-64.
-
2007: Engfeldt Torun; Tran Thuy; Orlova Anna; Widström Charles; Feldwisch Joachim; Abrahmsen Lars; Wennborg Anders; Karlström Amelie Eriksson; Tolmachev Vladimir
99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
European journal of nuclear medicine and molecular imaging 2007;34(11):1843-53.
-
2007: Persson Mikael; Sivaev Igor; Winberg Karl Johan; Gedda Lars; Malmström Per-Uno; Tolmachev Vladimir
In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):585-96.
-
2007: Orlova Anna; Feldwisch Joachim; Abrahmsén Lars; Tolmachev Vladimir
Update: affibody molecules for molecular imaging and therapy for cancer.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):573-84.
-
2007: Orlova Anna; Tran Thuy; Widström Charles; Engfeldt Torun; Eriksson Karlström Amelie; Tolmachev Vladimir
Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
International journal of molecular medicine 2007;20(3):397-404.
-
2007: Almqvist Ylva; Steffen Ann-Charlott; Lundqvist Hans; Jensen Holger; Tolmachev Vladimir; Sundin Anders
Biodistribution of 211At-labeled humanized monoclonal antibody A33.
Cancer biotherapy & radiopharmaceuticals 2007;22(4):480-7.
-
2007: Cheng Junping; Ekberg Tomas; Engström Mats; Nestor Marika; Jensen Holger J; Tolmachev Vladimir; Anniko Matti
Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
The Laryngoscope 2007;117(6):1013-8.
-
2007: Steffen Ann-Charlott; Almqvist Ylva; Chyan Ming-Kuan; Lundqvist Hans; Tolmachev Vladimir; Wilbur D Scott; Carlsson Jörgen
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.
Oncology reports 2007;17(5):1141-7.
-
2007: Engfeldt Torun; Orlova Anna; Tran Thuy; Bruskin Alexander; Widström Charles; Karlström Amelie Eriksson; Tolmachev Vladimir
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
European journal of nuclear medicine and molecular imaging 2007;34(5):722-33.
-
2007: Tolmachev Vladimir; Orlova Anna; Nilsson Fredrik Y; Feldwisch Joachim; Wennborg Anders; Abrahmsén Lars
Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.
Expert opinion on biological therapy 2007;7(4):555-68.
-
2007: Nilsson Fredrik Y; Tolmachev Vladimir
Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.
Current opinion in drug discovery & development 2007;10(2):167-75.
-
2007: Tolmachev Vladimir; Orlova Anna; Pehrson Rikard; Galli Joakim; Baastrup Barbro; Andersson Karl; Sandström Mattias; Rosik Daniel; Carlsson Jörgen; Lundqvist Hans; Wennborg Anders; Nilsson Fredrik Y
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Cancer research 2007;67(6):2773-82.
-
2007: Orlova Anna; Tolmachev Vladimir; Pehrson Rikard; Lindborg Malin; Tran Thuy; Sandström Mattias; Nilsson Fredrik Y; Wennborg Anders; Abrahmsén Lars; Feldwisch Joachim
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
Cancer research 2007;67(5):2178-86.
-
2007: Tran Thuy; Engfeldt Torun; Orlova Anna; Widström Charles; Bruskin Alexander; Tolmachev Vladimir; Karlström Amelie Eriksson
In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
Bioconjugate chemistry 2007;18(2):549-58.
-
2007: Tran Thuy; Orlova Anna; Sivaev Igor; Sandström Mattias; Tolmachev Vladimir
Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.
International journal of molecular medicine 2007;19(3):485-93.
-
2007: Fortin Marc-André; Orlova Anna; Malmström Per-Uno; Tolmachev Vladimir
Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma.
International journal of molecular medicine 2007;19(2):285-91.
-
2007: Persson Mikael; Gedda Lars; Lundqvist Hans; Tolmachev Vladimir; Nordgren Hans; Malmström Per-Uno; Carlsson Jörgen
[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
Cancer research 2007;67(1):326-31.
-
2007: Nestor Marika; Ekberg Tomas; Dring John; van Dongen Guus A M S; Wester Kenneth; Tolmachev Vladimir; Anniko Matti
Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2007;28(5):253-63.
-
2006: Almqvist Ylva; Steffen Ann-Charlott; Tolmachev Vladimir; Divgi Chaitanya R; Sundin Anders
In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Nuclear medicine and biology 2006;33(8):991-8.
-
2006: Höglund Johanna; Orlova Anna; Sundin Anders; Lundqvist Hans; Tolmachev Vladimir
Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated.
Oncology reports 2006;16(1):159-63.
-
2006: Steffen Ann-Charlott; Orlova Anna; Wikman Maria; Nilsson Fredrik Y; Ståhl Stefan; Adams Gregory P; Tolmachev Vladimir; Carlsson Jörgen
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.
European journal of nuclear medicine and molecular imaging 2006;33(6):631-8.
-
2006: Tolmachev Vladimir; Nilsson Fredrik Y; Widström Charles; Andersson Karl; Rosik Daniel; Gedda Lars; Wennborg Anders; Orlova Anna
111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(5):846-53.
-
2006: Orlova Anna; Magnusson Mikaela; Eriksson Tove L J; Nilsson Martin; Larsson Barbro; Höidén-Guthenberg Ingmarie; Widström Charles; Carlsson Jörgen; Tolmachev Vladimir; Ståhl Stefan; Nilsson Fredrik Y
Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
Cancer research 2006;66(8):4339-48.
-
2006: Orlova Anna; Bruskin Alexander; Sivaev Igor; Sjöberg Stefan; Lundqvist Hans; Tolmachev Vladimir
Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI).
Anticancer research 2006;26(2A):1217-23.
-
2006: Orlova Anna; Nilsson Fredrik Y; Wikman Maria; Widström Charles; Ståhl Stefan; Carlsson Jörgen; Tolmachev Vladimir
Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(3):512-9.
-
2006: Persson M I; Gedda L; Jensen H J; Lundqvist H; Malmström P-U; Tolmachev V
Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.
Oncology reports 2006;15(3):673-80.
-
2006: Carlsson J; Ren Z P; Wester K; Sundberg A L; Heldin N E; Hesselager G; Persson M; Gedda L; Tolmachev V; Lundqvist H; Blomquist E; Nistér M
Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.
Journal of neuro-oncology 2006;77(1):33-45.
-
2005: Persson Mikael; Tolmachev Vladimir; Andersson Karl; Gedda Lars; Sandström Mattias; Carlsson Jörgen
[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
European journal of nuclear medicine and molecular imaging 2005;32(12):1457-62.
-
2005: Mume Eskender; Orlova Anna; Larsson Barbro; Nilsson Ann-Sofie; Nilsson Fredrik Y; Sjöberg Stefan; Tolmachev Vladimir
Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
Bioconjugate chemistry 2005;16(6):1547-55.
-
2005: Velikyan Irina; Sundberg Asa Liljegren; Lindhe Orjan; Höglund A Urban; Eriksson Olof; Werner Eva; Carlsson Jorgen; Bergström Mats; Långström Bengt; Tolmachev Vladimir
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(11):1881-8.
-
2005: Kullberg Erika Bohl; Stenerlöw Bo; Ghirmai Senait; Lundqvist Hans; Malmström Per-Uno; Orlova Anna; Tolmachev Vladimir; Gedda Lars
An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay.
International journal of oncology 2005;27(5):1355-60.
-
2005: Nestor M; Persson M; van Dongen G A M S; Jensen H J; Lundqvist H; Anniko M; Tolmachev V
In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
European journal of nuclear medicine and molecular imaging 2005;32(11):1296-304.
-
2005: Almqvist Ylva; Orlova Anna; Sjöström Anna; Jensen Holger J; Lundqvist Hans; Sundin Anders; Tolmachev Vladimir
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.
Cancer biotherapy & radiopharmaceuticals 2005;20(5):514-23.
-
2005: Mume Eskender; Orlova Anna; Malmström Per-Uno; Lundqvist Hans; Sjöberg Stefan; Tolmachev Vladimir
Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET.
Nuclear medicine and biology 2005;32(6):613-22.
-
2005: Steffen Ann-Charlott; Wikman Maria; Tolmachev Vladimir; Adams Gregory P; Nilsson Fredrik Y; Ståhl Stefan; Carlsson Jörgen
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
Cancer biotherapy & radiopharmaceuticals 2005;20(3):239-48.
-
2005: Babaei Mohammad Hossein; Almqvist Ylva; Orlova Anna; Shafii Mohammad; Kairemo Kalevi; Tolmachev Vladimir
[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation.
Oncology reports 2005;13(6):1169-75.
-
2005: Ghirmai Senait; Mume Eskender; Tolmachev Vladimir; Sjöberg Stefan
Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives.
Carbohydrate research 2005;340(1):15-24.
-
2004: Sandström Mattias; Tolmachev Vladimir; Kairemo Kalevi; Lundqvist Hans; Lubberink Mark
Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT.
Physics in medicine and biology 2004;49(24):5419-32.
-
2004: Orlova Anna; Sjöstrom Anna; Lebeda Ondrej; Lundqvist Hans; Carlsson Jorgen; Tolmachev Vladimir
Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells.
Anticancer research 2004;24(6):4035-41.
-
2004: Cheng Junping; Persson Mikael; Tolmachev Vladimir; Siavaev Igor; Orlova Anna; Kairemo Kalevi; Anniko Matti
Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker.
Acta oto-laryngologica 2004;124(9):1078-85.
-
2004: Tolmachev Vladimir; Orlova Anna; Wei Qichun; Bruskin Alexander; Carlsson Jörgen; Gedda Lars
Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice.
Cancer biotherapy & radiopharmaceuticals 2004;19(4):491-501.
-
2004: Wikman M; Steffen A-C; Gunneriusson E; Tolmachev V; Adams G P; Carlsson J; Ståhl S
Selection and characterization of HER2/neu-binding affibody ligands.
Protein engineering, design & selection : PEDS 2004;17(5):455-62.
-
2004: Winberg Karl Johan; Persson Mikael; Malmström Per-Uno; Sjöberg Stefan; Tolmachev Vladimir
Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion.
Nuclear medicine and biology 2004;31(4):425-33.
-
2004: Sundberg Asa Liljegren; Gedda Lars; Orlova Anna; Bruskin Alexander; Blomquist Erik; Carlsson Jörgen; Tolmachev Vladimir
[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.
Cancer biotherapy & radiopharmaceuticals 2004;19(2):195-204.
-
2004: Lundqvist Hans; Carlsson Jörgen; Gedda Lars; Tolmachev Vladimir; Garske Ulrike; Kairemo Kalevi
[Radionuclide therapy--a possible way toward an improved treatment of cancer. The obstacle is the shortage of commercially available radionuclides for clinical use]
Läkartidningen 2004;101(11):1000-2, 1005-6.
-
2004: Bruskin Alexander; Sivaev Igor; Persson Mikael; Lundqvist Hans; Carlsson Jörgen; Sjöberg Stefan; Tolmachev Vladimir
Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI).
Nuclear medicine and biology 2004;31(2):205-11.
-
2004: Tolmachev Vladimir; Carlsson Jörgen; Lundqvist Hans
A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides.
Acta oncologica (Stockholm, Sweden) 2004;43(3):264-75.
-
2003: Tolmachev V; Orlova A; Lundqvist H
Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides.
Current medicinal chemistry 2003;10(22):2447-60.
-
2003: Sundberg Asa Liljegren; Almqvist Ylva; Orlova Anna; Blomquist Erik; Jensen Holger J; Gedda Lars; Tolmachev Vladimir; Carlsson Jörgen
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.
European journal of nuclear medicine and molecular imaging 2003;30(10):1348-56.
-
2003: Sundberg Asa Liljegren; Orlova Anna; Bruskin Alexander; Gedda Lars; Carlsson Jörgen; Blomquist Erik; Lundqvist Hans; Tolmachev Vladimir
[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent.
Cancer biotherapy & radiopharmaceuticals 2003;18(4):643-54.
-
2003: Nestor Marika; Persson Mikael; Cheng Junping; Tolmachev Vladimir; van Dongen Guus; Anniko Matti; Kairemo Kalevi
Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods.
Bioconjugate chemistry 2003;14(4):805-10.
-
2003: Sundberg Asa Liljegren; Almqvist Ylva; Tolmachev Vladimir; Carlsson Jörgen
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.
European journal of nuclear medicine and molecular imaging 2003;30(5):727-9.
-
2003: Beshara Soheir; Sörensen Jens; Lubberink Mark; Tolmachev Vladimir; Långström Bengt; Antoni Gunnar; Danielson Bo G; Lundqvist Hans
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography.
British journal of haematology 2003;120(5):853-9.
-
2002: Lubberink Mark; Tolmachev Vladimir; Widström Charles; Bruskin Alexander; Lundqvist Hans; Westlin Jan-Erik
110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002;43(10):1391-7.
-
2002: Orlova Anna; Höglund Johanna; Lubberink Mark; Lebeda Ondrej; Gedda Lars; Lundqvist Hans; Tolmachev Vladimir; Sundin Anders
Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry.
Cancer biotherapy & radiopharmaceuticals 2002;17(4):385-96.
-
2002: Lubberink Mark; Lundqvist Hans; Tolmachev Vladimir
Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy.
Physics in medicine and biology 2002;47(4):615-29.
-
2002: Lundqvist Hans; Tolmachev Vladimir
Targeting peptides and positron emission tomography.
Biopolymers 2002;66(6):381-92.
-
2002: Lindqvist Ulla; Tolmachev Vladimir; Kairemo Kalevi; Aström Gunnar; Jonsson Eva; Lundqvist Hans
Elimination of stabilised hyaluronan from the knee joint in healthy men.
Clinical pharmacokinetics 2002;41(8):603-13.
-
2000: Mårs U; Tolmachev V; Sundin A
Positron emission tomography of experimental melanoma with.
Nuclear medicine and biology 2000;27(8):845-9.
-
2000: Höglund J; Tolmachev V; Orlova A; Lundqvist H; Sundin A
Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET.
Nuclear medicine and biology 2000;27(8):837-43.
-
2000: Orlova A; Bruskin A; Sjöström A; Lundqvist H; Gedda L; Tolmachev V
Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells.
Nuclear medicine and biology 2000;27(8):827-35.
-
2000: Tolmachev V; Bernhardt P; Forssell-Aronsson E; Lundqvist H
114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide.
Nuclear medicine and biology 2000;27(2):183-8.
-
1999: Lubberink M; Tolmachev V; Beshara S; Lundqvist H
Quantification aspects of patient studies with 52Fe in positron emission tomography.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1999;51(6):707-15.
-
1999: Sundin J; Tolmachev V; Koziorowski J; Carlsson J; Lundqvist H; Welt S; Larson S; Sundin A
High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T.
Nuclear medicine and biology 1999;26(8):923-9.
-
1999: Zhao Q; Tolmachev V; Carlsson J; Lundqvist H; Sundin J; Janson J C; Sundin A
Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF.
Bioconjugate chemistry 1999;10(6):938-46.
-
1999: Tolmachev V; Koziorowski J; Sivaev I; Lundqvist H; Carlsson J; Orlova A; Gedda L; Olsson P; Sjöberg S; Sundin A
Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution.
Bioconjugate chemistry 1999;10(3):338-45.
-
1999: Garberg P; Engman L; Tolmachev V; Lundqvist H; Gerdes R G; Cotgreave I A
Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase.
The international journal of biochemistry & cell biology 1999;31(2):291-301.
-
1999: Lövqvist A; Lundqvist H; Lubberink M; Tolmachev V; Carlsson J; Sundin A
Kinetics of 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties.
Medical physics 1999;26(2):249-58.
-
1999: Beshara S; Lundqvist H; Sundin J; Lubberink M; Tolmachev V; Valind S; Antoni G; Långström B; Danielson B G
Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography.
British journal of haematology 1999;104(2):296-302.
-
1999: Beshara S; Lundqvist H; Sundin J; Lubberink M; Tolmachev V; Valind S; Antoni G; Långström B; Danielson B G
Kinetic analysis of 52Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography.
British journal of haematology 1999;104(2):288-95.
-
1999: Lubberink M; Lundqvist H; Westlin J E; Tolmachev V; Schneider H; Lövqvist A; Sundin A; Carlsson J
Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetry.
Acta oncologica (Stockholm, Sweden) 1999;38(3):343-9.
-
1999: Lundqvist H; Lubberink M; Tolmachev V; Lövqvist A; Sundin A; Beshara S; Bruskin A; Carlsson J; Westlin J E
Positron emission tomography and radioimmunotargeting--general aspects.
Acta oncologica (Stockholm, Sweden) 1999;38(3):335-41.
-
1999: Carlsson J; Blomquist E; Gedda L; Liljegren A; Malmström P U; Sjöström A; Sundin A; Westlin J E; Zhao Q; Tolmachev V; Lundqvist H
Conjugate chemistry and cellular processing of EGF-dextran.
Acta oncologica (Stockholm, Sweden) 1999;38(3):313-21.
-
1998: Bergström M; Lu L; Fasth K J; Wu F; Bergström-Pettermann E; Tolmachev V; Hedberg E; Cheng A; Långström B
In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(7):1273-9.
-
1998: Zhao Q; Blomquist E; Bolander H; Gedda L; Hartvig P; Janson J; Lundqvist H; Mellstedt H; Nilsson S; Nistèr M; Sundin A; Tolmachev V; Westlin J; Carlsson J
Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials.
International journal of molecular medicine 1998;1(4):693-702.
-
1998: Tolmachev V; Lundqvist H; Einarsson L
Production of 61Cu from a natural nickel target.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1998;49(1-2):79-81.
Sign-in to see more